Richard D. Carvajal
Melanoma oncologist who led the tebentafusp programme in the United States and defined targeted therapy for rare melanoma subtypes.
Overview
Richard Carvajal co-led the tebentafusp development programme including the pivotal IMCgp100-202 trial in metastatic uveal melanoma and the early trials of MEK inhibition in uveal melanoma, and led studies of imatinib in KIT-mutant melanoma. He directs medical oncology at Northwell and continues to focus on rare melanoma subtypes.
Pages like this
not linked directly; found by shared links- PersonPaul Nathan
Shares IMCgp100-202, gp100 (PMEL), Tebentafusp, Uveal melanoma and the tag uveal-melanoma.
- CompanyImmunocore
Shares IMCgp100-202, Tebentafusp, Uveal melanoma, Melanoma.
- ProductBrenetafusp
Shares Tebentafusp, Uveal melanoma, T-cell engagers (bispecific), Melanoma.
- TermHLA-A*02:01 restriction
Shares Tebentafusp, Uveal melanoma, T-cell engagers (bispecific), Melanoma.
- IdeaTCR therapeutics for non-HLA-A*02 patients
Shares Tebentafusp, T-cell engagers (bispecific), Melanoma.
- TrialSSGXVIII/AIO (adjuvant imatinib in GIST)
- InstitutionOxford Cancer – Oxford University Hospitals and University of Oxford
Shares gp100 (PMEL), Tebentafusp, T-cell engagers (bispecific), Melanoma.
- PersonCharles D. Blanke